Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839911 | 1.00 | DRD2 (0.54) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL14157832 | 1.00 | DRD2 (0.54) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL873500 | 1.00 | DRD2 (0.54) | DRD2HTR1ADRD1HTR1BHTR2A | |
| Hydrochloric Acid SCHEMBL8823809 | 0.98 | DRD2 (0.53) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL9441617 | 0.81 | HTR1A (0.54) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL8886915 | 0.81 | HTR1A (0.54) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL4505997 | 0.78 | DRD2 (0.52) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL14157823 | 0.78 | DRD2 (0.52) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL19054489 | 0.78 | HTR7 (0.38) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL4749715 | 0.78 | HTR1B (0.44) | DRD2HTR1ADRD1HTR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5650524-A | Process for preparing (R)-3-amino-5-methoxychroman | ASTRA AKTIEBOLAG (SE) | 1997-07-22 | — | — | US | claimed |
| EP-0703229-A2 | Process for the preparation of (R)-3-amino-5-methoxychroman | Astra Aktiebolag (SE) | 1996-03-27 | — | — | EP | claimed |
| US-20240417419-A1 | C-TERMINAL HSP90 INHIBITORS | UNIV KANSAS (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4403552-A2 | C-TERMINAL HSP90-INHIBITORS | The University of Kansas (US) | 2024-07-24 | — | — | EP | disclosed |
| US-12024536-B2 | C-terminal HSP90 inhibitors | UNIVERSITY OF KANSAS (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3656758-B1 | INTERMEDIATES FOR THE PREPARATION OF C-TERMINAL HSP90 INHIBITORS | UNIV KANSAS (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230102047-A1 | C-TERMINAL HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11390640-B2 | C-terminal Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2022-07-19 | — | — | US | disclosed |
| US-20210188891-A1 | C-TERMINAL HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| CN-107474085-B | Hsp 90C-terminal inhibitor and pharmaceutical composition and application thereof | 堪萨斯大学 | 2021-05-11 | — | — | CN | disclosed |
| US-10882881-B2 | C-terminal Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2021-01-05 | — | — | US | disclosed |
| EP-0571243-A1 | Thiochromane derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1993-11-24 | — | — | EP | disclosed |
| US-5252578-A | Treatment of disorders of teh serotoninergic system | ADIR ET COMPAGNIE (FR) | 1993-10-12 | — | — | US | disclosed |
| EP-0538222-A1 | 3-(N-Isopropyl-N-n-propylamino)-5-(N-isopropyl)carbamoylchroman as a selective 5-hydroxytryptamine receptor stimulant | Astra Aktiebolag (SE) | 1993-04-21 | — | — | EP | disclosed |
| WO-1993007135-A1 | 3-(N-ISOPROPYL-N-N-PROPYLAMINO)-5-(N-ISOPROPYL)CARBAMOYLCHROMAN | AKTIEBOLAGET ASTRA (SE) | 1993-04-15 | — | — | WO | disclosed |
| EP-0460169-A1 | NEW CHROMAN AND THIOCHROMAN DERIVATIVES. | ASTRA AB (SE) | 1991-12-11 | — | — | EP | disclosed |
| EP-0452204-A1 | 3-Aminochromane derivatives, procedure for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-10-16 | — | — | EP | disclosed |
| WO-1991009853-A1 | NEW CHROMAN AND THIOCHROMAN DERIVATIVES | AKTIEBOLAGET ASTRA (SE) | 1991-07-11 | — | — | WO | disclosed |
| EP-0279150-A1 | 5-Oxy-substituted-3-aminochroman compounds, processes for their preparation, pharmaceutical compositions containing them and methods of treatment therewith | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1988-08-24 | — | — | EP | disclosed |
| WO-1988004654-A1 | 5-HYDROXY-3-AMINOCHROMAN COMPOUNDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF TREATMENT THEREWITH | Astra Läkemedel Aktiebolag (SE) | 1988-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882881-B2 | C-terminal Hsp90 inhibitors | HSP90AB2P, HSP90AB1, HSP90B1 | DRD2 4749/4885HTR1A 4348/4885DRD1 4716/4885 |
| US-11390640-B2 | C-terminal Hsp90 inhibitors | HSP90AB2P, HSP90AB1, HSP90B1 | DRD2 4749/4885HTR1A 4348/4885DRD1 4716/4885 |
| US-20230102047-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | DRD2 4749/4885HTR1A 4348/4885DRD1 4716/4885 |
| US-20240417419-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | DRD2 4749/4885HTR1A 4348/4885DRD1 4716/4885 |
| US-12024536-B2 | C-terminal HSP90 inhibitors | HSP90AB2P, HSP90AB1, HSP90B1 | DRD2 4749/4885HTR1A 4348/4885DRD1 4716/4885 |
| US-20210188891-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | DRD2 4749/4885HTR1A 4348/4885DRD1 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.